Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.93 USD | +4.94% | +3.21% | +71.61% |
May. 09 | Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 02 | Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target | MT |
Financials (USD)
Sales 2024 * | 10.22M | Sales 2025 * | 7.75M | Capitalization | 1.49B |
---|---|---|---|---|---|
Net income 2024 * | -187M | Net income 2025 * | -192M | EV / Sales 2024 * | 83.1 x |
Net cash position 2024 * | 638M | Net cash position 2025 * | 333M | EV / Sales 2025 * | 149 x |
P/E ratio 2024 * |
-8.78
x | P/E ratio 2025 * |
-10.8
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.42% |
Latest transcript on Spyre Therapeutics, Inc.
1 day | +4.94% | ||
1 week | +3.21% | ||
Current month | +11.81% | ||
1 month | -4.30% | ||
3 months | +54.20% | ||
6 months | +289.15% | ||
Current year | +71.61% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 23-06-21 |
Russell Cox
CHM | Chairman | 60 | 15-05-31 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 36.93 | +4.94% | 429,293 |
24-05-09 | 35.19 | +6.57% | 185,724 |
24-05-08 | 33.02 | -3.56% | 245,077 |
24-05-07 | 34.24 | -4.28% | 186,999 |
24-05-06 | 35.77 | -0.03% | 208,175 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+71.61% | 1.49B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- SYRE Stock